American Society of Hirudotherapy

Successful Microsurgical Replantation of Amputated Penis: A Case Report and Review of Literature

Akhoondinasab MR, Farahmand HR, Zahedi A, Saraee A (2023) · World Journal of Plastic Surgery · n=1

Observational study: FDA has cleared Hirudo medicinalis as a medical device (K040187, June 21 2004) for venous congestion in surgical flaps. Other uses are off-label or investigational.Study record: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.

Study Profile

Design
case report of microsurgical penile replantation with postoperative leech therapy (Iran University of Medical Sciences, Tehran)
Sample size (n)
1
Intervention
Microsurgical replantation of completely amputated penis after 9 hours ischemia; postoperative leech therapy 3 sessions (30 minutes each, leeches detached spontaneously) for venous congestion
Main result
Successful replantation with limited and predictable necrosis at penoscrotal junction (debrided and skin grafted); complete vascular and sensory restoration; psychiatric follow-up arranged for self-mutilation patient
Follow-up duration
Postoperative hospitalization + outpatient follow-up

Key Findings

  • Successful penile replantation after 9-hour ischemia
  • Three sessions of leech therapy for venous congestion control
  • Complete vascular and sensory recovery
  • Predictable, limited necrosis only at penoscrotal junction
  • Integrated psychiatric care for self-mutilation patient

Limitations

  • Single case - hypothesis-generating only
  • Cannot generalize from psychiatric self-mutilation context
  • 9-hour ischemia uniquely long
  • No long-term functional outcomes assessed
  • Standard practice does not differ from non-leech penile replants

Clinical Implications

Akhoondinasab 2023 confirms leech therapy utility in penile microsurgical replantation - a rare but high-stakes K040187 indication. For US clinicians, the case reinforces that the device's primary US indication (venous congestion in flap-based reconstruction) extends to atypical genitourinary trauma. Early leech initiation (postoperative day 2) and self-detachment endpoint (30 minutes) align with standard protocols.

Related studies

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.